Get notified regarding key financial metrics and revenue changes at Boehringer IngelheimLearn more
Banner background

Boehringer Ingelheim Revenue

Boehringer Ingelheim revenue was €20.62 b in FY, 2021

Embed Graph

Summary - Funding Rounds

Founding Date

1885

Boehringer Ingelheim Revenue Breakdown

Embed Graph

Boehringer Ingelheim revenue breakdown by business segment: 20.8% from Animal Health, 74.2% from Human Pharmaceuticals and 5.0% from Other

Boehringer Ingelheim revenue breakdown by geographic segment: 44.4% from Americas, 23.8% from Asia/Australia/Africa and 31.8% from Europe

Boehringer Ingelheim Income Statement

Annual

EURFY, 2019FY, 2020FY, 2021

Revenue

19.0b19.6b20.6b

Cost of goods sold

2.9b2.6b2.8b

Gross profit

16.1b17.0b17.8b

Gross profit Margin, %

85%87%86%

General and administrative expense

5.4b5.6b5.7b

Operating expense total

14.6b16.1b16.1b

Depreciation and amortization

1.2b1.4b1.1b

EBIT

3.8b4.6b4.7b

EBIT margin, %

18%24%23%

Interest expense

526.0m559.0m430.0m

Interest income

54.0m31.0m15.0m

Pre tax profit

3.5b4.3b4.4b

Income tax expense

775.0m1.2b962.0m

Net Income

2.7b3.1b3.4b

Boehringer Ingelheim Balance Sheet

Annual

EURFY, 2017FY, 2018FY, 2019

Cash

3.1b4.3b2.2b

Accounts Receivable

3.1b3.5b4.2b

Prepaid Expenses

334.0m377.0m313.0m

Inventories

3.1b3.3b3.6b

Current Assets

10.7b12.2b11.2b

PP&E

3.9b4.3b4.8b

Goodwill

19.0m26.0m77.0m

Total Assets

28.4b30.9b33.5b

Accounts Payable

880.0m855.0m830.0m

Total Debt

439.0m420.0m256.0m

Total Liabilities

17.7b18.6b18.8b

Common Stock

178.0m178.0m178.0m

Total Equity

10.7b12.3b14.7b

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

2.7 x2.5 x2.3 x

Boehringer Ingelheim Cash Flow

Annual

EURFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

1.8b(229.0m)2.1b2.7b

Depreciation and Amortization

620.0m963.0m1.1b1.2b

Accounts Receivable

(315.0m)(478.0m)(590.0m)

Inventories

(249.0m)305.0m(229.0m)(274.0m)

Accounts Payable

151.0m(60.0m)8.0m9.0m

Cash From Operating Activities

2.9b2.6b3.0b3.3b

Purchases of PP&E

(645.0m)(872.0m)(950.0m)(1.1b)

Cash From Investing Activities

(133.0m)(5.1b)(1.4b)(1.4b)

Long-term Borrowings

(722.0m)(948.0m)2.0m(185.0m)

Cash From Financing Activities

(1.0b)(1.2b)(208.0m)(1.0b)

Net Change in Cash

1.7b(3.7b)1.4b894.0m

Income Taxes Paid

987.0m1.1b1.2b1.1b

Boehringer Ingelheim Ratios

EURFY, 2016

Boehringer Ingelheim Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Active Clinical Studies

500400400

Manufacturing Facilities (Animal Health)

191616

Manufacturing Facilities (Human Pharmaceuticals)

191620

New Products

200300200

Projects in Pipeline

90

Boehringer Ingelheim Human Capital

Job Roles

Y, 2021Y, 2020Y, 2019
Research and Development19.3%18.3%17.9%
Sales and Marketing33.5%35.6%36.2%
Administration12.6%12.1%12%
Production33.2%32.6%32.5%
Other1.4%1.4%1.4%

Gender

Y, 2021Y, 2019
Male (Leadership), percent30.5%31%
Female (Leadership), percent19.5%19%
Male, percent25.5%26%
Female, percent24.5%24%

Boehringer Ingelheim Employee Rating

4.12952 votes
Culture & Values
4
Work/Life Balance
4
Senior Management
3.5
Salary & Benefits
4
Career Opportunities
3.5
Source